Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Neuroendocrinology 2004;80(suppl 1):3–7

Epidemiology of Neuroendocrine Tumours

Taal B.G.a · Visser O.b

Author affiliations

aDepartment of Gastroenterology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital and bComprehensive Cancer Centre Amsterdam, Amsterdam, The Netherlands

Corresponding Author

B.G. Taal

Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital

Plesmanlaan 121

NL–1066 CX Amsterdam (The Netherlands)

Tel. +31 20 5122566, Fax +31 20 5122578, E-Mail b.taal@nki.nl

Do you have an account?

Login Information

Contact Information

By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.

I have read the Karger Terms and Conditions and agree.


Neuroendocrine tumours account for only 0.5% of all malignancies. The incidence is approximately 2/100,000 with a female preponderance under the age of 50 years due to appendiceal location. The main primary sites are the gastrointestinal tract (62–67%) and the lung (22–27%). Presentation with metastatic disease accounts for 12–22%. In the last decades, the incidence has been rising. This might be due to more awareness, improved diagnostic tools or a change in definition. Most neuroendocrine tumours are mainly sporadic, but association with the multiple endocrine neoplasia type 1 syndrome and clustering within families is known. Also an increased risk of secondary cancers has been reported, but numbers are small. The 5-year survival is mainly associated with stage: 93% in local disease, 74% in regional disease and 19% in metastatic disease. In metastatic disease, survival increased since 1992, when treatment with octreotide became largely available in the Netherlands.

© 2004 S. Karger AG, Basel


  1. Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 1999;40:858–868.
  2. Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH: Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996;14:1829–1838.
  3. Taal BG, Hoefnagel C, Boot H, Valdes Olmos R, Rutgers M: Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol 2000;11:1437–1443.
  4. Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG: Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003;97:1609–1615.
  5. Newton JN, Swerdlow AJ, dos Santos Silva IM, Vessey MP, Grahmae-Smith DG, Primatesta P, Reynolds DJM: The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 1994;70:939–942.
  6. Westergaard T, Frisch M, Melbye M: Carcinoid tumors in Denmark 1978–1989 and the risk of subsequent cancers. A population-based study. Cancer 1995;76:106–109.
  7. Crocetti E, Buiatti E, Amorosi A: Epidemiology of carcinoid tumours in central Italy. Eur J Epidemiol 1997;13:357–359.
  8. Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C: Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974–1997. Br J Cancer 2000;83:952–955.
  9. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG: Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2,391 patients. Ann Oncol 2001;12:1295–1300.
  10. Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 2001;92:2204–2210.
  11. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934–959.
  12. Tomassetti P, Migliori M, Lalli S, Campana D, Tomassetti V, Corinaldesi R: Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol 2001;12(suppl 2):S95–S99.
  13. Levi F, Randimbison L, Franceschi S, La Vecchia C: Descriptive epidemiology of malignant carcinoids in the Swiss Canton of Vaud. Int J Cancer 1993;53:1036–1037.
  14. Hemminki K, Li X: Familial carcinoid tumors and subsequent cancers: A nation-wide epidemiologic study from Sweden. Int J Cancer 2001;94:444–448.
  15. Kaerlev L, Teglbjaerg PS, Sabroe S, Kolstad HA, Ahrens W, Eriksson M, et al: Occupational risk factors for small bowel carcinoid tumor: A European population-based case-control study. J Occup Environ Med 2002;44:516–522.
  16. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM: Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000;10:2186–2187.
  17. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH: Pulmonary neuroendocrine tumors: Incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002;37:127–135.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: October 15, 2004

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 2

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: https://www.karger.com/NEN